Home » Scientific Sessions » 2023 » Page 7

  • Outstanding Educator awardee emphasizes importance of multiple ‘voices’ in the continuum of diabetes care

    Outstanding Educator awardee emphasizes importance of multiple ‘voices’ in the continuum of diabetes care

    A. Enrique Caballero, MD, advocates for thoughtfully designed diabetes education and prevention programs tailored to “speak to” the different audiences for which they are intended in order to optimize diabetes care and achieve better outcomes. He is the recipient of this year’s Outstanding Educator in Diabetes Award.

  • Panel examines measures of behavioral markers for diabetes self-management

    Panel examines measures of behavioral markers for diabetes self-management

    Various self-assessment tools exist to help patients with diabetes monitor their daily activities and provide their care teams with insights into glucose levels. Methods for tracking behavioral markers include sleep monitoring and actigraphy devices to track physical activity. Soohyun Nam, PhD, APRN, ANP-BC, FAHA, FAAN, discussed ecological momentary assessments.

  • Researchers weigh in on dietary management options

    Researchers weigh in on dietary management options

    Dietary choices are crucial for managing type 2 diabetes. Experts including Roy Taylor, MD, shared their perspectives on nutrition programs that have helped patients reduce or manage type 2 diabetes while also living healthier lives. These programs incorporate low-calorie diets, low-carb diets, and glycemic excursion minimization.

  • First phase 3 results for high-dose oral semaglutide to be released in San Diego

    First phase 3 results for high-dose oral semaglutide to be released in San Diego

    Vanita R. Aroda, MD, will share results from two trials, OASIS 1 and PIONEER PLUS, and discuss the effectiveness of higher dose semaglutide in treating patients with type 2 diabetes as well as patients with obesity without type 2 diabetes. She will discuss how a high-dose semaglutide regimen can help patients reach their health goals.

  • Investigators to trace ongoing impact of DCCT/EDIC trial results in treating type 1 diabetes

    Investigators to trace ongoing impact of DCCT/EDIC trial results in treating type 1 diabetes

    Forty years after the launch of the Diabetes Control and Complications Trial, the Epidemiology of Diabetes Interventions and Complications study continues to observe and report on 1,000 patients. Gayle Lorenzi, RN, CDCES, who manages the San Diego DCCT/EDIC site, and other investigators will discuss how the data gleaned from this sustained research has transformed management…

  • Experts will discuss beta-cell identity across the lifespan

    Experts will discuss beta-cell identity across the lifespan

    Raphael Scharfmann, PhD, will provide insight on the earliest beta cells: fetal pancreatic beta cells. His focus will be on the human fetal pancreas and what it can reveal about beta-cell identity. Other panelists will discuss postnatal beta cells and beta-cell aging.

  • Panelists to give overview of updates to the Standards of Care in Diabetes

    Panelists to give overview of updates to the Standards of Care in Diabetes

    A panel of experts will take a closer look at changes to the American Diabetes Association® Standards of Care in Diabetes. Eric L. Johnson, MD, said that while many cornerstones of diabetes care remain in place, several topics warrant new emphasis, including sleep health, social determinants of health, hypertension, and medications.

  • Experts to debate therapeutic approaches to aging-related metabolic disease and diabetes

    Experts to debate therapeutic approaches to aging-related metabolic disease and diabetes

    Two experts will present research on eliminating senescent cells that impact diabetes and aging-related metabolic disease. James L. Kirkland, MD, PhD, will discuss the use of senolytic drugs, and Anil Bhushan, PhD, will share his immunotherapy approach to eliminate senescent cells.

  • Physician-scientists to address new opportunities for treatment of cardiovascular residual risk

    Physician-scientists to address new opportunities for treatment of cardiovascular residual risk

    A panel of diabetes and cardiovascular experts, including Jan Borén, MD, PhD, will discuss cardiovascular disease and people with diabetes. The symposium will cover contributing factors to cardiovascular residual risk, new drug targets, and methods to assess disease.

  • Researchers examine adipocyte communication in metabolic processes

    Researchers examine adipocyte communication in metabolic processes

    As part of a panel in the ADA Diabetes Journal Symposium, Jonathan Z. Long, PhD, will discuss signaling pathways in energy metabolism, including exercise-induced mediators of body adiposity. He will also share cutting-edge research using a cell-type-specific proteomic approach.

0